Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, ERP, DIV

Abbott Reports Third-Quarter 2017 Results


ABBOTT PARK, Ill., Oct. 18, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2017.

"We're very pleased with our performance and the steady cadence of innovative new product launches that are contributing to growth," said Miles D. White, chairman and chief executive officer, Abbott. "We're well-positioned to achieve the upper end of our initial full-year EPS guidance range."

* See note on comparable operational growth below.

THIRD-QUARTER BUSINESS OVERVIEW
Note: Management believes that measuring sales growth rates on a comparable operational basis is an appropriate way for investors to best understand the underlying performance of the business.

Comparable operational sales growth excludes the impact of exchange and for Total Abbott and Medical Devices, also includes prior year results for St. Jude Medical, which was acquired on Jan. 4, 2017, and excludes prior year and current year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017. Comparable operational sales growth also reflects a reduction to St. Jude Medical's historic sales related to administrative fees paid to conform to Abbott's presentation, as further described in Form 8-K issued on April 18, 2017.

Following are sales by business segment and commentary for the third quarter and first nine months of 2017:

Total Company

($ in millions)










% Change vs. 3Q16



Sales 3Q17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total *


2,313


4,516


6,829


40.6


23.5


28.8


2.0


7.6


5.6

Nutrition


759


1,009


1,768


0.5


1.0


0.8


0.5


1.1


0.8

Diagnostics


369


910


1,279


2.0


6.9


5.4


2.0


6.6


5.2

Established Pharmaceuticals


--


1,171


1,171


 n/a 


15.7


15.7


 n/a 


14.3


14.3

Medical Devices


1,177


1,420


2,597


126.8


79.5


98.2


3.1


7.8


5.6


* Total Abbott sales from continuing operations include Other Sales of $14 million. In 2016, the AMO business, which was divested during the first quarter 2017, was reported as part of the Medical Devices group. Comparable operational growth rates above exclude results from the AMO business.










% Change vs. 9M16



Sales 9M17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total *


6,997


12,804


19,801


44.8


19.8


27.6


3.0


4.5


3.9

Nutrition


2,262


2,879


5,141


1.7


(2.2)


(0.5)


1.7


(1.1)


0.1

Diagnostics


1,125


2,585


3,710


6.0


3.6


4.3


6.0


4.7


5.1

Established Pharmaceuticals


--


3,142


3,142


 n/a 


9.1


9.1


 n/a 


8.0


8.0

Medical Devices


3,504


4,084


7,588


130.5


73.2


95.6


2.8


5.8


4.4


* In 2017, total Abbott sales from continuing operations include Other Sales of $220 million, including sales of $175 million from the AMO business, which was divested during the first quarter 2017. In 2016, the AMO business was reported as part of the Medical Devices group. Comparable operational growth rates above exclude results from the AMO business.


n/a = Not Applicable.


Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Third-quarter 2017 worldwide sales of $6.8 billion increased 28.8 percent on a reported basis. On a comparable operational basis, worldwide sales increased 5.6 percent. Refer to tables titled "Non-GAAP Reconciliation of Comparable Historical Revenue" for a reconciliation of comparable historical revenue.

 

Nutrition

($ in millions)










% Change vs. 3Q16



Sales 3Q17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


759


1,009


1,768


0.5


1.0


0.8


0.5


1.1


0.8

Pediatric


436


539


975


5.2


(2.4)


0.8


5.2


(2.6)


0.7

Adult


323


470


793


(5.3)


5.2


0.7


(5.3)


5.6


0.9










% Change vs. 9M16



Sales 9M17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


2,262


2,879


5,141


1.7


(2.2)


(0.5)


1.7


(1.1)


0.1

Pediatric


1,327


1,562


2,889


6.8


(6.1)


(0.6)


6.8


(5.1)


-

Adult


935


1,317


2,252


(4.8)


3.0


(0.3)


(4.8)


4.1


0.3

Worldwide Nutrition sales increased 0.8 percent on a reported and operational basis in the third quarter.

Worldwide Pediatric Nutrition sales increased 0.8 percent on a reported basis in the third quarter, including a favorable 0.1 percent effect of foreign exchange, and increased 0.7 percent on an operational basis. Sales growth in the quarter was led by above-market growth in the U.S. with continued strong performance across Abbott's portfolio of infant and pediatric nutrition products. As expected, sales growth in China improved sequentially versus the prior quarter, which was offset by continued challenging market conditions in certain other international countries.

Worldwide Adult Nutrition sales increased 0.7 percent on a reported basis in the third quarter, including an unfavorable 0.2 percent effect of foreign exchange, and increased 0.9 percent on an operational basis. International sales growth of 5.2 percent on a reported basis and 5.6 percent on an operational basis was led by growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes-specific nutrition brand. As expected, U.S. sales growth was impacted by competitive and market dynamics.

 

Diagnostics

($ in millions)










% Change vs. 3Q16



Sales 3Q17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


369


910


1,279


2.0


6.9


5.4


2.0


6.6


5.2

Core Laboratory


230


803


1,033


4.6


6.0


5.7


4.6


5.9


5.6

Molecular


37


78


115


(13.8)


12.7


2.7


(13.8)


10.1


1.1

Point of Care


102


29


131


2.9


17.4


5.8


2.9


16.7


5.6










% Change vs. 9M16



Sales 9M17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


1,125


2,585


3,710


6.0


3.6


4.3


6.0


4.7


5.1

Core Laboratory


678


2,286


2,964


10.1


2.8


4.3


10.1


4.1


5.4

Molecular


123


218


341


(12.3)


9.6


0.6


(12.3)


8.9


0.1

Point of Care


324


81


405


6.1


12.3


7.3


6.1


12.7


7.4

Worldwide Diagnostics sales increased 5.4 percent on a reported basis in the third quarter, including a favorable 0.2 percent effect of foreign exchange, and increased 5.2 percent on an operational basis.

Core Laboratory Diagnostics sales increased 5.7 percent on a reported basis in the third quarter, including a favorable 0.1 percent effect of foreign exchange, and increased 5.6 percent on an operational basis. Growth in the quarter was led by continued share gains globally. Internationally, Abbott continued the early roll-out of its recently launched Alinitytm systems for the core laboratory, including "Alinity c" for clinical chemistry, "Alinity i" for immunoassay diagnostics and "Alinity s" for blood and plasma screening. Abbott expects to initiate the launch of its Alinity systems in the U.S. in 2018.

Molecular Diagnostics sales increased 2.7 percent on a reported basis in the third quarter, including a favorable 1.6 percent effect of foreign exchange, and increased 1.1 percent on an operational basis. Continued growth in infectious disease testing, Abbott's core area of focus in the molecular diagnostics market, was offset by a planned scale down in other testing areas.

Point of Care Diagnostics sales increased 5.8 percent on a reported basis in the third quarter, including a favorable 0.2 percent effect of foreign exchange, and increased 5.6 percent on an operational basis as this business continues to build and expand its presence in targeted developed and emerging markets.

 

Established Pharmaceuticals

($ in millions)










% Change vs. 3Q16



Sales 3Q17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


--


1,171


1,171


 n/a 


15.7


15.7


 n/a 


14.3


14.3

Key Emerging Markets


--


885


885


 n/a 


18.5


18.5


 n/a 


18.0


18.0

Other


--


286


286


 n/a 


7.6


7.6


 n/a 


4.0


4.0










% Change vs. 9M16



Sales 9M17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


--


3,142


3,142


 n/a 


9.1


9.1


 n/a 


8.0


8.0

Key Emerging Markets


--


2,413


2,413


 n/a 


13.0


13.0


 n/a 


11.6


11.6

Other


--


729


729


 n/a 


(2.3)


(2.3)


 n/a 


(2.5)


(2.5)

Established Pharmaceuticals sales increased 15.7 percent on a reported basis in the third quarter, including a favorable 1.4 percent effect of foreign exchange, and increased 14.3 percent on an operational basis.

Key Emerging Markets comprise several countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these key geographies increased 18.5 percent on a reported basis and 18.0 percent on an operational basis in the third quarter, led by strong growth across several countries, including double-digit growth in Brazil, Russia, India and China.

As expected, sales in India were positively impacted by purchasing patterns following the implementation of a new Goods and Services Tax system that lowered second quarter sales in that country. Total Established Pharmaceuticals, Key Emerging Markets, and India sales growth increased double-digits with and without this impact.

 

Medical Devices

($ in millions)










% Change vs. 3Q16



Sales 3Q17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


1,177


1,420


2,597


126.8


79.5


98.2


3.1


7.8


5.6

Cardiovascular and Neuromodulation


1,093


1,131


2,224


258.2


180.7


214.1


4.6


2.8


3.6

Rhythm Management


250


261


511


 n/m 


 n/m 


 n/m 


(15.6)


(8.4)


(12.1)

Electrophysiology


147


195


342


 n/m 


 n/m 


 n/m 


7.9


12.9


10.7

Heart Failure


131


39


170


 n/m 


 n/m 


 n/m 


10.7


27.4


14.0

Vascular


292


432


724


11.1


21.5


17.1


(0.6)


0.7


0.2

Structural Heart


109


160


269


172.3


242.5


210.1


13.7


9.1


11.0

Neuromodulation


164


44


208


 n/m 


 n/m 


 n/m 


55.9


19.6


46.8

Diabetes Care


84


289


373


(13.0)


37.6


21.7


(13.0)


33.9


19.1










% Change vs. 9M16



Sales 9M17


Reported


Comparable Operational



U.S.


Int'l


Total


U.S.


Int'l


Total


U.S.


Int'l


Total

Total


3,504


4,084


7,588


130.5


73.2


95.6


2.8


5.8


4.4

Cardiovascular and Neuromodulation


3,264


3,323


6,587


247.1


169.2


202.9


2.9


1.6


2.3

Rhythm Management


783


791


1,574


 n/m 


 n/m 


 n/m 


(15.7)


(5.7)


(10.9)

Electrophysiology


446


555


1,001


 n/m 


 n/m 


 n/m 


10.4


10.7


10.5

Heart Failure


363


108


471


 n/m 


 n/m 


 n/m 


0.3


10.4


2.5

Vascular


891


1,267


2,158


9.1


16.4


13.3


(2.3)


(1.9)


(2.1)

Structural Heart


320


473


793


177.8


227.5


205.5


14.8


9.8


11.7

Neuromodulation


461


129


590


 n/m 


 n/m 


 n/m 


61.0


17.4


49.0

Diabetes Care


240


761


1,001


0.4


28.2


20.2


0.4


29.2


21.0


n/m = Percent change is not meaningful.

Worldwide Medical Devices sales increased 98.2 percent on a reported basis in the third quarter. On a comparable operational basis, sales increased 5.6 percent. Refer to tables titled "Non-GAAP Reconciliation of Comparable Historical Revenue" for a reconciliation of comparable historical revenue.

In Cardiovascular and Neuromodulation, worldwide sales were led by double-digit growth in Electrophysiology, Structural Heart, Heart Failure and Neuromodulation. Growth in Structural Heart was driven by the continued double-digit growth of MitraClip®, Abbott's market-leading device for the minimally-invasive treatment of mitral regurgitation. In Heart Failure, during the third quarter, Abbott received U.S. FDA approval for its HeartMate 3 system, which helps a weak heart pump blood through the body for patients with advanced heart failure. In Neuromodulation, another quarter of strong double-digit growth was led by several recently launched products for the treatment of chronic pain and movement disorders. As expected, Rhythm Management sales in the U.S. were impacted by continued competitive dynamics in the magnetic resonance (MR)-conditional category of products. In the quarter, Abbott received FDA approval for MR-conditional labeling for its Ellipse implantable cardioverter defibrillator (ICD), which significantly enhances its competitive position in this category of the market. 

Worldwide Diabetes Care sales increased 21.7 percent on a reported basis in the third quarter, including a favorable 2.6 percent effect of foreign exchange, and increased 19.1 percent on an operational basis. Strong double-digit international sales growth was led by FreeStyle Libre, Abbott's revolutionary sensor-based glucose monitoring system. In September, Abbott received U.S. FDA approval for FreeStyle Libre as a replacement1 for finger stick blood glucose monitoring. This revolutionary technology is the only system available that comes factory-calibrated, thus eliminating the need for daily finger sticks that are required to calibrate other systems currently available. During the quarter, Abbott also obtained national reimbursement for FreeStyle Libre in Japan and the United Kingdom for people with diabetes, both Type 1 and Type 2, on insulin therapy. 

ABBOTT NARROWS FULL-YEAR EARNINGS-PER-SHARE GUIDANCE

Abbott is narrowing its full-year 2017 earnings per share guidance range, which continues to reflect double-digit growth. Abbott now projects its earning per share from continuing operations under Generally Accepted Accounting Principles (GAAP) to be $0.97 to $0.99 for the full year 2017.

Projected diluted earnings per share from continuing operations on an adjusted basis is now $2.48 to $2.50 for the full year 2017, which represents an increase at the mid-point of the guidance range.

Abbott forecasts net specified items for the full year 2017 of approximately $1.51 per share. Specified items include acquisition-related expenses, intangible amortization expense, charges associated with cost reduction initiatives and other expenses, partially offset by a gain on the sale of the AMO business.

Abbott is issuing fourth-quarter 2017 guidance for diluted earnings per share from continuing operations under GAAP of $0.28 to $0.30. Abbott forecasts specified items for the fourth quarter 2017 of $0.44 primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.72 to $0.74 for the fourth quarter.

ABBOTT DECLARES 375TH QUARTERLY DIVIDEND

On Sept. 14, 2017, the board of directors of Abbott declared the company's quarterly dividend of $0.265 per share. Abbott's cash dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

Abbott has increased its dividend payout for 45 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 94,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available later that day.

? Private Securities Litigation Reform Act of 1995 ?
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors'' to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1 Finger sticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.          

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2017 and 2016

(in millions, except per share data)

(unaudited)




3Q17


3Q16


% Change


Net Sales


$6,829


$5,302


28.8










Cost of products sold, excluding amortization expense


2,857


2,285


25.1


Amortization of intangible assets


501


140


n/m


Research and development


562


352


59.3


Selling, general, and administrative


2,099


1,628


28.9


Total Operating Cost and Expenses


6,019


4,405


36.7










Operating earnings


810


897


(9.7)










Interest expense, net


182


95


90.7


Net foreign exchange (gain) loss


(6)


9


n/m


Other expense, net


8


972


(99.2)

1)

Earnings (Loss) from Continuing Operations before taxes


626


(179)


n/m










Tax expense on Earnings (Loss) from Continuing Operations


65


178


(63.5)

2)

Earnings (Loss) from Continuing Operations


561


(357)


n/m










Earnings from Discontinued Operations, net of taxes


42


28


53.1


Gain on Sale of Discontinued Operations, net of taxes


--


--




Net Earnings from Discontinued Operations, net of taxes


42


28


53.1










Net Earnings (Loss)


$603


$(329)


n/m










Earnings from Continuing Operations, excluding 








Specified Items, as described below


$1,158


$883


31.1

3)









Diluted Earnings (Loss) per Common Share from:








Continuing Operations


$0.32


$(0.24)


n/m


Discontinued Operations


0.02


0.02


--


Total


$0.34


$(0.22)


n/m










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$0.66


$0.59


11.9

3)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,754


1,476



4)



NOTES:


See tables below for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes below.



1)

2016 Other expense, net includes a charge of $947 million related to an adjustment of Abbott's holdings of Mylan N.V. ordinary shares to reflect the share price as of Sept. 30, 2016.



2)

2016 Tax expense on Earnings (Loss) from Continuing Operations includes the impact of the non-deductible Mylan equity investment adjustment and the recognition of deferred taxes associated with the sale of AMO, partially offset by a net tax benefit of approximately $105 million as a result of the resolution of various tax positions from prior years.



3)

2017 Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $597 million, or $0.34 per share, for intangible amortization expense and expenses primarily associated with acquisitions, restructuring actions and other expenses.




2016 Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.240 billion, or $0.83 per share, for intangible amortization expense, an adjustment to the equity investment in Mylan, expenses primarily associated with acquisitions, including bridge facility fees, charges related to cost reduction initiatives and other expenses and the recognition of deferred taxes associated with the sale of AMO, partially offset by the favorable impact of a net tax benefit as a result of the resolution of various tax positions from prior years.



4)

2016 Average number of common shares outstanding excludes approximately 6.7 million shares related to dilutive common stock options, which would be antidilutive.

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2017 and 2016

(in millions, except per share data)

(unaudited)




9M17


9M16


% Change


Net Sales


$19,801


$15,520


27.6










Cost of products sold, excluding amortization expense


9,074


6,712


35.2


Amortization of intangible assets


1,415


429


n/m


Research and development


1,622


1,079


50.3


Selling, general, and administrative


6,655


5,063


31.5


Total Operating Cost and Expenses


18,766


13,283


41.3










Operating earnings


1,035


2,237


(53.7)










Interest expense, net


569


203


n/m


Net foreign exchange (gain) loss


(34)


497


n/m

1)

Other (income) expense, net


(1,157)


999


n/m

2)

Earnings from Continuing Operations before taxes


1,657


538


n/m










Tax expense on Earnings from Continuing Operations


440


240


83.6

3)

Earnings from Continuing Operations


1,217


298


n/m










Earnings from Discontinued Operations, net of taxes


88


288


(69.4)


Gain on Sale of Discontinued Operations, net of taxes


--


16


n/m


Net Earnings from Discontinued Operations, net of taxes


88


304


(71.0)

4)









Net Earnings


$1,305


$602


n/m










Earnings from Continuing Operations, excluding 








Specified Items, as described below


$3,097


$2,310


34.1

5)









Diluted Earnings per Common Share from:








Continuing Operations


$0.69


$0.20


n/m


Discontinued Operations


0.05


0.20


(75.0)

4)

Total


$0.74


$0.40


85.0










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$1.76


$1.55


13.5

5)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,746


1,483






NOTES:


See tables below for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes below.



1)

2016 Net foreign exchange (gain) loss includes a loss of $481 million related to the revaluation of Abbott's net monetary assets in Venezuela using the Dicom exchange rate, which is the Venezuelan government's official floating exchange rate.



2)

2017 Other (income) expense, net includes a pretax gain of $1.163 billion from the sale of the AMO business.




2016 Other (income) expense, net includes a charge of $947 million related to an adjustment of Abbott's holdings of Mylan N.V. ordinary shares to reflect the share price as of Sept. 30, 2016.



3)

2017 Tax expense on Earnings from Continuing Operations includes the tax associated with a $1.163 billion pretax gain on the sale of the AMO business.




2016 Tax expense on Earnings from Continuing Operations includes the impact of a net tax benefit of approximately $250 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela and an adjustment to the equity investment in Mylan and the recognition of deferred taxes associated with the sale of the AMO business.



4)

2017 Earnings and Diluted Earnings per Common Share from Discontinued Operations, net of taxes primarily relates to a net tax benefit as a result of the resolution of various tax positions from prior years.




2016 Earnings and Diluted Earnings per Common Share from Discontinued Operations, net of taxes primarily reflect the impact of a net tax benefit of $289 million as a result of the resolution of various tax positions from prior years.



5)

2017 Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.880 billion, or $1.07 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions, partially offset by a gain on the sale of the AMO business.




2016 Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.012 billion, or $1.35 per share, for intangible amortization expense, the foreign exchange loss related to Venezuela, an adjustment to the equity investment in Mylan, expenses associated with acquisitions, including bridge facility fees, other charges related to cost reduction initiatives and other expenses and the recognition of deferred taxes associated with the sale of AMO, partially offset by the favorable impact of a net tax benefit as a result of the resolution of various tax positions from prior years.

NON-GAAP RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING OPERATIONS

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Third Quarter Ended September 30, 2017 and 2016

(in millions, except per share data) 

(unaudited)




3Q17



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales

Intangible Amortization


$501


$(501)


--



Gross Margin


3,471


580


$4,051


59.3%

R&D


562


(91)


471


6.9%

SG&A


2,099


(90)


2,009


29.4%

Other expense, net


8


1


9



Earnings (Loss) from Continuing Operations before taxes 


626


760


1,386



Tax expense on Earnings (Loss) from Continuing Operations

65


163


228



Earnings (Loss) from Continuing Operations


561


597


1,158



Diluted Earnings (Loss) per Share from Continuing Operations

$0.32


$0.34


$0.66



Specified items reflect intangible amortization expense of $501 million and other expenses of $259 million, primarily associated with acquisitions, restructuring actions and other expenses. See tables titled "Details of Specified Items"  for additional details regarding specified items.



3Q16



As
Reported
(GAAP)


Specified
Items


As
Adjusted 


% to
Sales

Intangible Amortization


$140


$(140)


--



Gross Margin


2,877


158


$3,035


57.3%

R&D


352


(22)


330


6.2%

SG&A


1,628


(53)


1,575


29.7%

Interest expense, net


95


(70)


25



Net foreign exchange (gain) loss


9


(4)


5



Other expense, net


972


(957)


15



Earnings (Loss) from Continuing Operations before taxes


(179)


1,264


1,085



Tax expense on Earnings (Loss) from Continuing Operations


178


24


202



Earnings (Loss) from Continuing Operations


(357)


1,240


883



Diluted Earnings (Loss) per Share from Continuing Operations

$(0.24)


$0.83


$0.59



Specified items reflect intangible amortization expense of $140 million, an adjustment to the equity investment in Mylan of $947 million, and other expenses of $177 million, primarily associated with acquisitions, including bridge facility fees, charges related to cost reduction initiatives and other expenses and the recognition of approximately $130 million of deferred taxes associated with the sale of AMO, partially offset by a net tax benefit of approximately $105 million as a result of the resolution of various tax positions from prior years. See tables titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Nine Months Ended September 30, 2017 and 2016

(in millions, except per share data) 

(unaudited)




9M17



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales

Intangible Amortization


$1,415


$(1,415)


--



Gross Margin


9,312


2,459


$11,771


59.5%

R&D


1,622


(146)


1,476


7.5%

SG&A


6,655


(595)


6,060


30.6%

Interest expense, net


569


(19)


550



Other (income) expense, net


(1,157)


1,167


10



Earnings from Continuing Operations before taxes 


1,657


2,052


3,709



Tax expense on Earnings from Continuing Operations


440


172


612



Earnings from Continuing Operations


1,217


1,880


3,097



Diluted Earnings per Share from Continuing Operations


$0.69


$1.07


$1.76



Specified items reflect intangible amortization expense of $1.415 billion and other expenses of $1.800 billion, primarily associated with acquisitions, including approximately $840 million of inventory step-up amortization related to St. Jude Medical, charges related to restructuring actions and other expenses, partially offset by a gain of $1.163 billion from the sale of the AMO business. See tables titled "Details of Specified Items" for additional details regarding specified items.



9M16



As
Reported
(GAAP)


Specified
Items


As
Adjusted 


% to
Sales

Intangible Amortization


$429


$(429)


--



Gross Margin


8,379


500


$8,879


57.2%

R&D


1,079


(68)


1,011


6.5%

SG&A


5,063


(150)


4,913


31.7%

Interest expense, net


203


(139)


64



Net foreign exchange (gain) loss


497


(481)


16



Other (income) expense, net


999


(962)


37



Earnings from Continuing Operations before taxes


538


2,300


2,838



Tax expense on Earnings from Continuing Operations


240


288


528



Earnings from Continuing Operations


298


2,012


2,310



Diluted Earnings per Share from Continuing Operations


$0.20


$1.35


$1.55



Specified items reflect intangible amortization expense of $429 million, an adjustment to the equity investment in Mylan of $947 million, the impact of the foreign exchange loss in Venezuela of $481 million, and other expenses of $443 million, primarily associated with acquisitions, including bridge facility fees, and charges related to cost reduction initiatives and other expenses and the recognition of approximately $130 million of deferred taxes associated with the sale of AMO, partially offset by a net tax benefit of approximately $250 million as a result of the resolution of various tax positions from prior years. See tables titled "Details of Specified Items" for additional details regarding specified items.

RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS
A reconciliation of the third-quarter tax rates for continuing operations for 2017 and 2016 is shown below:




3Q17


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$626


$65


10.4%

1)

Specified items


760


163




Excluding specified items


$1,386


$228


16.5%














3Q16


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$(179)


$178


(99.5%)


Specified items


1,264


24




Excluding specified items


$1,085


$202


18.6%




1)

Reported tax rate on a GAAP basis for the third quarter of 2017 includes the impact of approximately $30 million in excess tax benefits associated with share-based compensation.

A reconciliation of the year-to-date tax rates for continuing operations for 2017 and 2016 is shown below:




9M17


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$1,657


$440


26.6%

2)

Specified items


2,052


172




Excluding specified items


$3,709


$612


16.5%














9M16


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$538


$240


44.5%


Specified items


2,300


288




Excluding specified items


$2,838


$528


18.6%




2)

Reported tax rate on a GAAP basis for 2017 includes the impact of taxes associated with a $1.163 billion pre-tax gain on the sale of the AMO business and the impact of approximately $90 million in excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Comparable Historical Revenue

Third Quarter Ended September 30, 2017 and 2016

($ in millions) (unaudited)




3Q17


3Q16


% Change vs. 3Q16



Abbott
Reported


Divested
Businesses


Comparable
Revenue


Abbott
Reported


Acquired
St. Jude
Businessa)


AMO


Comparable
Revenue




Comparable










Reported


Reported


Operationalb)






















Total Company


6,829


--


6,829


5,302


1,425


(296)


6,431


28.8


6.2


5.6

U.S.


2,313


--


2,313


1,645


742


(118)


2,269


40.6


2.0


2.0

Int'l


4,516


--


4,516


3,657


683


(178)


4,162


23.5


8.5


7.6

Total Medical Devices


2,597


--


2,597


1,310


1,425


(296)


2,439


98.2


6.5


5.6

U.S.


1,177


--


1,177


519


742


(118)


1,143


126.8


3.1


3.1

Int'l


1,420


--


1,420


791


683


(178)


1,296


79.5


9.5


7.8

Cardiovascular and Neuromodulation

2,224


--


2,224


708


1,425


--


2,133


214.1


4.3


3.6

U.S.


1,093


--


1,093


305


742


--


1,047


258.2


4.6


4.6

Int'l


1,131


--


1,131


403


683


--


1,086


180.7


4.0


2.8

Rhythm Management


511


--


511


--


577


--


577


 n/m 


(11.4)


(12.1)

U.S.


250


--


250


--


297


--


297


 n/m 


(15.6)


(15.6)

Int'l


261


--


261


--


280


--


280


 n/m 


(7.1)


(8.4)

Electrophysiology


342


--


342


3


306


--


309


 n/m 


10.6


10.7

U.S.


147


--


147


3


133


--


136


 n/m 


7.9


7.9

Int'l


195


--


195


--


173


--


173


 n/m 


12.7


12.9

Heart Failure


170


--


170


--


148


--


148


 n/m 


14.8


14.0

U.S.


131


--


131


--


118


--


118


 n/m 


10.7


10.7

Int'l


39


--


39


--


30


--


30


 n/m 


31.2


27.4

Vascular


724


--


724


618


101


--


719


17.1


0.8


0.2

U.S.


292


--


292


262


32


--


294


11.1


(0.6)


(0.6)

Int'l


432


--


432


356


69


--


425


21.5


1.8


0.7

Structural Heart


269


--


269


87


152


--


239


210.1


12.4


11.0

U.S.


109


--


109


40


56


--


96


172.3


13.7


13.7

Int'l


160


--


160


47


96


--


143


242.5


11.6


9.1

Neuromodulation


208


--


208


--


141


--


141


 n/m 


47.7


46.8

U.S.


164


--


164


--


106


--


106


 n/m 


55.9


55.9

Int'l


44


--


44


--


35


--


35


 n/m 


23.0


19.6


a) Reflects reported actuals for St. Jude Medical, excluding results from the vascular closure business, as well as a reduction to St. Jude Medical sales related to the reclassification of fees paid to group purchasing organizations from the Selling, general, and administrative line.

b) In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Comparable Historical Revenue

Nine Months Ended September 30, 2017 and 2016

($ in millions) (unaudited)




9M17


9M16


% Change vs. 9M16



Abbott
Reported


Divested
Businessesa)


Comparable
Revenue


Abbott
Reported


Acquired
St. Jude
Businessb)


AMO


Comparable
Revenue




Comparable










Reported


Reported


Operationalc)






















Total Company


19,801


(187)


19,614


15,520


4,282


(872)


18,930


27.6


3.6


3.9

U.S.


6,997


(84)


6,913


4,831


2,227


(342)


6,716


44.8


3.0


3.0

Int'l


12,804


(103)


12,701


10,689


2,055


(530)


12,214


19.8


4.0


4.5

Total Medical Devices


7,588


(12)


7,576


3,879


4,282


(872)


7,289


95.6


3.9


4.4

U.S.


3,504


(6)


3,498


1,520


2,227


(342)


3,405


130.5


2.8


2.8

Int'l


4,084


(6)


4,078


2,359


2,055


(530)


3,884


73.2


5.0


5.8

Cardiovascular and Neuromodulation

6,587


(12)


6,575


2,175


4,282


--


6,457


202.9


1.8


2.3

U.S.


3,264


(6)


3,258


940


2,227


--


3,167


247.1


2.9


2.9

Int'l


3,323


(6)


3,317


1,235


2,055


--


3,290


169.2


0.8


1.6

Rhythm Management


1,574


--


1,574


--


1,773


--


1,773


 n/m 


(11.3)


(10.9)

U.S.


783


--


783


--


929


--


929


 n/m 


(15.7)


(15.7)

Int'l


791


--


791


--


844


--


844


 n/m 


(6.5)


(5.7)

Electrophysiology


1,001


--


1,001


10


900


--


910


 n/m 


10.0


10.5

U.S.


446


--


446


10


395


--


405


 n/m 


10.4


10.4

Int'l


555


--


555


--


505


--


505


 n/m 


9.7


10.7

Heart Failure


471


--


471


--


461


--


461


 n/m 


2.3


2.5

U.S.


363


--


363


--


361


--


361


 n/m 


0.3


0.3

Int'l


108


--


108


--


100


--


100


 n/m 


9.8


10.4

Vascular


2,158


(12)


2,146


1,905


299


--


2,204


13.3


(2.5)


(2.1)

U.S.


891


(6)


885


815


91


--


906


9.1


(2.3)


(2.3)

Int'l


1,267


(6)


1,261


1,090


208


--


1,298


16.4


(2.7)


(1.9)

Structural Heart


793


--


793


260


452


--


712


205.5


11.3


11.7

U.S.


320


--


320


115


164


--


279


177.8


14.8


14.8

Int'l


473


--


473


145


288


--


433


227.5


9.0


9.8

Neuromodulation


590


--


590


--


397


--


397


 n/m 


48.8


49.0

U.S.


461


--


461


--


287


--


287


 n/m 


61.0


61.0

Int'l


129


--


129


--


110


--


110


 n/m 


16.8


17.4


a) Reflects sales related to the AMO and St. Jude Medical vascular closure businesses prior to divesting in the first quarter 2017.

b) Reflects reported actuals for St. Jude Medical, excluding results from the vascular closure business, as well as a reduction to St. Jude Medical sales related to the reclassification of fees paid to group purchasing organizations from the Selling, general, and administrative line.

c) In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2017

(in millions, except per share data)

(unaudited)




Acquisition or
Divestiture-
related (a)


Restructuring
and Cost
Reduction
Initiatives (b)


Intangible
Amortization


Other (c)


Total
Specifieds

Gross Margin


$               26


$               53


$           501


$         -


$       580

R&D


(11)


(74)


--


(6)


(91)

SG&A


(84)


(7)


--


1


(90)

Other (income) expense, net


16


--


--


(15)


1

Earnings from Continuing Operations before taxes


$             105


$             134


$           501


$      20


760

Tax expense on Earnings from Continuing Operations (d)










163

Earnings from Continuing Operations










$       597

Diluted Earnings per Share from Continuing Operations










$      0.34



The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations".



a) 

Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Divestiture-related expenses include incremental costs to separate the divested businesses as well as bankers' fees and costs for legal, accounting, tax, and other services related to the divestitures.

b) 

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. Any gains related to the divestiture of a facility as part of a restructuring program are also included in this category.

c) 

Other expense primarily relates to the impairment of a financial instrument and the acquisition of an R&D asset.

d) 

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2016

(in millions, except per share data)

(unaudited)




Acquisition or
Divestiture-
related (a)


Restructuring
and Cost
Reduction
Initiatives (b)


Mylan Equity
Investment
Adjustment
(c)


Venezuela
Devaluation 


Intangible
Amortization


Other
(d)


Total
Specifieds

Gross Margin


$                 3


$                      15


$                  --


$              --


$            140


$    --


$                  158

R&D


(5)


2


--


--


--


(19)


(22)

SG&A


(38)


(14)


--


(1)


--


--


(53)

Interest expense, net


(70)


--


--


--


--


--


(70)

Net foreign exchange (gain) loss


--


--


--


(4)


--


--


(4)

Other (income) expense, net


(11)


--


(947)


1


--


--


(957)

Earnings from Continuing Operations before taxes


$             127


$                      27


$               947


$              4


$            140


$  19


1,264

Tax expense on Earnings from Continuing Operations (e)













24

Earnings from Continuing Operations













$               1,240

Diluted Earnings per Share from Continuing Operations













$                 0.83



The table above provides additional details regarding the specified items described tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations".



a) 

Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions and integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, severance, and the integration of processes and business activities. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Divestiture-related expenses include incremental costs to separate the divested businesses.

b) 

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c) 

Mylan equity investment adjustment expense reflects the adjustment of Abbott's holding of Mylan N.V. ordinary shares due to a decline in the fair value of the securities which was considered by Abbott to be other than temporary.

d) 

Other expense relates to the impairment of an R&D asset.

e) 

Reflects the net tax benefit associated with the specified items and a net tax benefit of approximately $105 million primarily as a result of the resolution of various tax positions from prior years, partially offset by the recognition of approximately $130 million of deferred taxes associated with the sale of AMO.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2017

(in millions, except per share data)

(unaudited)




Acquisition or
Divestiture-
related (a)


Restructuring
and Cost
Reduction
Initiatives (b)


Intangible
Amortization


Other (c)


Total
Specifieds

Gross Margin


$             870


$             174


$         1,415


$          -


$      2,459

R&D


(37)


(103)


--


(6)


(146)

SG&A


(570)


(26)


--


1


(595)

Interest expense, net


(19)


--


--


--


(19)

Other (income) expense, net


1,216


(34)


--


(15)


1,167

Earnings from Continuing Operations before taxes


$             280


$             337


$         1,415


$       20


2,052

Tax expense on Earnings from Continuing Operations (d)









172

Earnings from Continuing Operations









$      1,880

Diluted Earnings per Share from Continuing Operations









$        1.07



The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations".



a) 

Acquisition-related expenses include bankers' fees and costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Other (income) expense, net includes the gain on the sale of the AMO business. Divestiture-related expenses include incremental costs to separate the divested businesses as well as bankers' fees and costs for legal, accounting, tax, and other services related to the divestitures.

b) 

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. Any gains related to the divestiture of a facility as part of a restructuring program are also included in this category.

c) 

Other expense primarily relates to the impairment of a financial instrument and the acquisition of an R&D asset.

d) 

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2016

(in millions, except per share data)

(unaudited)




Acquisition or
Divestiture-
related (a)


Restructuring
and Cost
Reduction
Initiatives (b)


Mylan Equity
Investment
Adjustment
(c)


Venezuela
Devaluation
(d)


Intangible
Amortization


Other
(e)


Total
Specifieds

Gross Margin


$               13


$                      43


$                  --


$             15


$            429


$    --


$                 500

R&D


(7)


1


--


--


--


(62)


(68)

SG&A


(79)


(61)


--


(10)


--


--


(150)

Interest expense, net


(139)


--


--


--


--


--


(139)

Net foreign exchange (gain) loss


--


--


--


(481)


--


--


(481)

Other (income) expense, net


(14)


--


(947)


(1)


--


--


(962)

Earnings from Continuing Operations before taxes


$             252


$                    103


$              947


$           507


$            429


$  62


2,300

Tax expense on Earnings from Continuing Operations (f)













288

Earnings from Continuing Operations













$               2,012

Diluted Earnings per Share from Continuing Operations













$                1.35


The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations".



a) 

Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions and integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, severance, and the integration of processes and business activities. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Divestiture-related expenses include incremental costs to separate the divested businesses.

b) 

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. Any gains related to the divestiture of a facility as part of a restructuring program are also included in this category.

c) 

Mylan equity investment adjustment expense reflects the adjustment of Abbott's holding of Mylan N.V. ordinary shares due to a decline in the fair value of the securities which was considered by Abbott to be other than temporary.

d) 

Venezuela devaluation expenses include the foreign exchange loss of $480 million related to the revaluation of Abbott's net monetary assets in Venezuela using the Dicom exchange rate as well as inventory and other asset impairments in Venezuela related to the move to the Dicom exchange rate. The Dicom rate is the Venezuelan government's official floating exchange rate.

e) 

Other expense relates to the impairment of an R&D asset.

f) 

Reflects the net tax benefit associated with the specified items and a net tax benefit of approximately $250 million primarily as a result of the resolution of various tax positions from prior years, partially offset by the recognition of approximately $130 million of deferred taxes associated with the sale of AMO.

 

Abbott Logo (PRNewsFoto/Abbott)

 

SOURCE Abbott


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: